JANXHIGH SIGNALFINANCIAL10-K

JANX experienced a dramatic deterioration in cash position, falling from $430.6M to $52.3M while operating losses substantially expanded.

The company burned through nearly 88% of its cash reserves in a single year while operating cash outflow roughly doubled, creating potential funding pressure for this clinical-stage biotech. With only $52.3M remaining and current burn rates, JANX may need to raise additional capital soon to continue operations and clinical development programs.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

JANX's financial position weakened dramatically, with cash and equivalents plummeting from $430.6M to $52.3M as operating cash outflow roughly doubled to -$82.2M. R&D expenses grew substantially to $125.9M from $68.4M, driving meaningfully larger net losses and operating losses. The combination of accelerated cash burn and depleted cash reserves signals potential near-term funding needs for continued operations.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-87.8%
$430.6M→$52.3M

Cash declined 87.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Cash Flow
Cash Flow
-87.7%
-$43.8M→-$82.2M

Operating cash flow fell 87.7% — earnings quality concerns; investigate working capital changes and non-cash items.

R&D Expense
P&L
+84.1%
$68.4M→$125.9M

R&D investment increased 84.1% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
-64.7%
-$69.0M→-$113.6M

Net income declined 64.7% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-59.5%
-$98.8M→-$157.7M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Liabilities
Balance Sheet
+43.2%
$17.5M→$25.0M

Current liabilities surged 43.2% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+15.5%
$38.7M→$44.7M

Liabilities increased 15.5% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.
Our (or the third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.
Overview We are an innovative clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying our proprietary technologies to our Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms.
Our initial focus is on developing a novel class of TRACTr therapeutics designed to target clinically validated TCE drug targets, while overcoming the liabilities associated with prior generations of TCEs.
+7 more — sign up free →
REMOVED
Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.
Our (or the third parties with whom we work) actual or perceived failure to comply with current or future federal, state and foreign laws, regulations, contracts, self-regulatory schemes, industry standards and other obligations relating to privacy and security could lead to regulatory investigations or actions (which could include civil or criminal penalties), private litigation (including class claims) and mass arbitration demands, adverse publicity, disruptions of our business operations and other adverse business consequences.
Overview We are an innovative clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer.
Our proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr).
Our initial focus is on developing a novel class of TRACTr therapeutics designed to target clinically validated TCE drug targets, but overcome liabilities associated with prior generations of TCEs.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →